Amedisys (NASDAQ:AMED) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Amedisys (NASDAQ:AMEDGet Rating) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the health services provider’s stock.

A number of other research firms also recently issued reports on AMED. Truist Financial dropped their price target on Amedisys from $115.00 to $97.00 in a research report on Thursday, May 4th. Cantor Fitzgerald assumed coverage on Amedisys in a research report on Thursday, April 20th. They set a “neutral” rating and a $87.00 price target on the stock. Stephens reissued an “equal weight” rating and set a $103.00 price target on shares of Amedisys in a research report on Tuesday, March 14th. SVB Securities dropped their price target on Amedisys from $96.00 to $81.00 in a research report on Friday, May 5th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $115.00 price target on shares of Amedisys in a research report on Monday, February 27th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $108.94.

Amedisys Stock Performance

Shares of Amedisys stock opened at $78.70 on Wednesday. The stock’s fifty day moving average is $76.75 and its two-hundred day moving average is $84.31. The company has a market capitalization of $2.56 billion, a PE ratio of 22.88, a price-to-earnings-growth ratio of 2.22 and a beta of 1.02. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 0.33. Amedisys has a 52 week low of $69.36 and a 52 week high of $131.32.

Amedisys (NASDAQ:AMEDGet Rating) last announced its quarterly earnings data on Thursday, May 4th. The health services provider reported $1.00 EPS for the quarter, beating the consensus estimate of $0.86 by $0.14. The company had revenue of $556.39 million for the quarter, compared to the consensus estimate of $558.98 million. Amedisys had a return on equity of 14.35% and a net margin of 5.02%. Amedisys’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.23 EPS. As a group, analysts expect that Amedisys will post 4.25 earnings per share for the current year.

Insider Buying and Selling at Amedisys

In other Amedisys news, insider Michael Paul North sold 5,908 shares of the stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $86.43, for a total value of $510,628.44. Following the completion of the sale, the insider now directly owns 4,164 shares in the company, valued at $359,894.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amedisys

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James & Associates raised its stake in shares of Amedisys by 6.5% in the first quarter. Raymond James & Associates now owns 11,101 shares of the health services provider’s stock worth $1,913,000 after purchasing an additional 680 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Amedisys by 9.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock worth $413,000 after purchasing an additional 202 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Amedisys by 22.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock worth $590,000 after purchasing an additional 620 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Amedisys by 40.4% in the first quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock worth $1,310,000 after purchasing an additional 2,193 shares during the last quarter. Finally, Citigroup Inc. raised its stake in shares of Amedisys by 6.4% in the first quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock worth $2,287,000 after purchasing an additional 803 shares during the last quarter. 96.17% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.

See Also

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.